• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Home
  • DOPT ORDERS 2020
  • FinMin Orders 2020
  • Railway Orders 2020
  • Contact Us

7th Pay Commission Latest news

Central Government Employees News

  • DOPPW Orders
  • 7th Pay Commission
  • Dearness Allowance
  • Dearness Relief
  • CSD Price List
  • Defence
    • Defence Pension
You are here: Home / COVID-19 / Indian Initiative to fight COVID-19

Trending
Central Government Holidays for the year 2021 – DOPT “hot”
Holidays List 2021 for Central Government Employees “hot”
AICPIN for the month of January 2021 “hot”
Freezing of Dearness Allowance & Dearness Relief till July 2021

Indian Initiative to fight COVID-19

April 21, 2020 pcadmin Leave a Comment

Indian Initiative to fight COVID-19

CSIR supports efforts to develop a drug to save lives of critically ill patients suffering from Gram-negative sepsis

CSIR, is now initiating a randomized, blinded, two arms, active comparator-controlled clinical trial to evaluate the efficacy of the drug for reducing mortality (deaths) in critically ill COVID-19 patients

The Drugs Controller General of India (DCGI) has approved the trial and it will start soon at multiple hospitals

It is found to be extremely safe in patients and no systemic side effects are associated with its use


The Council of Scientific and Industrial Research (CSIR), through its flagship New Millennium Indian Technology Leadership Initiative (NMITLI) program, has been supporting Cadila Pharmaceuticals Ltd., Ahmedabad since 2007 for developing a drug to save lives of critically ill patients suffering from Gram-negative sepsis. This entire development effort (pre-clinical and clinical studies) has been supervised by CSIR appointed Monitoring Committee. The drug has been shown to reduce the mortality of critically ill patients by more than half. It also leads to faster recovery of organ dysfunction seen in this condition. It is now approved for marketing in India. It will be available commercially as Sepsivac® from Cadila Pharmaceuticals Ltd.

This is a moment of pride for all of us as, despite best efforts, no other drug was approved in Gram-negative sepsis for reducing mortality (death) globally.

In Gram-negative sepsis as well as in critically ill COVID-19 patients, there is an altered immune response leading to a massive change in their cytokine profile. The drug modulates the immune system of the body and thereby inhibits the cytokine storm leading to reduced mortality and faster recovery.

Looking at similarities between clinical characteristics of patients suffering from COVID-19 and Gram-negative sepsis, CSIR, is now initiating a randomized, blinded, two arms, active comparator-controlled clinical trial to evaluate the efficacy of the drug for reducing mortality (deaths) in critically ill COVID-19 patients. The Drugs Controller General of India (DCGI) has approved the trial and it will start soon at multiple hospitals.

The drug contains heat-killed Mycobacterium W (Mw). >It is found to be extremely safe in patients and no systemic side effects are associated with its use.It can be used concurrently with any other therapies required in the management of such critically ill patients without any restriction. Its unique properties include boosting protective immunity (Th1, TLR2 agonist) and suppressing non-protective response (Th2).

CSIR has also planned to evaluate Mw for faster recovery of hospitalized COVID-19 infected patients and minimize the spread of disease through them as well for providing prophylaxis to persons coming in contact with COVID-19 infected patients like family members and health care workers.

[#CSIRFightsCovid19]

****

PIB

Filed Under: COVID-19

Also Read

EPFO extended social security benefits to the subscribers of J&K and Ladakh

EPFO extended social security benefits to the subscribers of J&K and Ladakh

March 4, 2021 By pcadmin Leave a Comment

EPFO extended social security benefits to the subscribers of J&K and Ladakh CBT meet on 4th March, first time in Srinagar after extension EPF Act in the UTs Consequent upon implementation of EPF & MP Act, 1952 in the UTs of J&K and Ladakh w.e.f. 31st October, 2019, EPFO has extended … [Read More...] about EPFO extended social security benefits to the subscribers of J&K and Ladakh

Code On Wages (Central Advisory Board) Rules, 2021

Code On Wages (Central Advisory Board) Rules, 2021

March 4, 2021 By pcadmin Leave a Comment

Code On Wages (Central Advisory Board) Rules, 2021 MINISTRY OF LABOUR AND EMPLOYMENT NOTIFICATION New Delhi, the 1st March, 2021 G.S.R. 143(E).—Whereas the draft of certain rules which the Central Government proposes to make, in exercise of the powers conferred by sub-section (1) of section 67 … [Read More...] about Code On Wages (Central Advisory Board) Rules, 2021

Income Tax

Clarification in respect of residency under Income-tax Act, 1961

March 4, 2021 By pcadmin Leave a Comment

Clarification in respect of residency under Income-tax Act, 1961 The Central Board of Direct taxes (CBDT) has received various representations requesting for relaxation in determination of residential status for previous year 2020-21 from individuals who had come on a visit to India during the … [Read More...] about Clarification in respect of residency under Income-tax Act, 1961

Extension of CGHS facilities to beneficiaries outside India.

Extension of CGHS facilities to beneficiaries outside India.

March 4, 2021 By pcadmin Leave a Comment

Extension of CGHS facilities to beneficiaries outside India. File NO.S.1103011/2021-EHS (by E-mail) Government of India Ministry of Health & Family Welfare Department of Health & Family Welfare (EHS Section) Dated, the 02nd March, 2021 Nirman Bhawan, New Delhi To Shri T.K. … [Read More...] about Extension of CGHS facilities to beneficiaries outside India.

Regularization of absence during COVID-19 pandemic lockdown period

Regularization of absence during COVID-19 pandemic lockdown period – DOPT

March 3, 2021 By pcadmin Leave a Comment

Clarification on regularization of absence during COVID-19 pandemic lockdown period - DOPT O.M No. 13020/1/2019-Estt(L) dated 01.03.2021 No. 13020/1/2019-Estt(L) Government of India Ministry of Personnel, Public Grievances and Pensions Department of Personnel & Training Old JNU Campus, … [Read More...] about Regularization of absence during COVID-19 pandemic lockdown period – DOPT

Reader Interactions

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Primary Sidebar

All About Pension

All about Pension

Latest DOPT Orders

Regularization of absence during COVID-19 pandemic lockdown period – DOPT

Modernization of Non-Statutory Departmental Canteens located in Central Government Offices : DOPT

Swachh Bharat Mission-Departmental Canteens

Opening of Departmental Canteens in Central Government Offices.

Government servants at all levels are to attend office on all working days without any exemption to any category of employees

Latest Finmin Orders

Rate of interest for purchase of Computer during 2021-22 – FINMIN

Clarification on Cash Management Guidelines – FINMIN

Clarification regarding Special Cash Package equivalent in lieu of LTC Fare for CG Employees during the block 2018-21

CGEGIS 1980 – Table of Benefits from Jan to March 2021

One time relaxation in Transport Allowance during COVID-19 pandemic – FINMIN

Latest Railway Orders

Conveyance Allowance at revised rates to Railway Medical Officers

Holidays to be observed in Central Government Offices during the year 2021: Railway Board Order

Grant of disability pension, comprising service element and disability element to pre-2006 disability pensioners

Re-classification of cities for the purpose HRA to Railway Employees

33% of Railways Officers and staff attend office with staggered timings

Categories

Copyright © 2021